Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021, according to Lannett.  Originally developed by GlaxoSmithKline (GSK), Advair Diskus is approved as a maintenance therapy to ease breathing difficulties in patients with chronic obstructive pulmonary disease…

You must be logged in to read/download the full post.